Tecovirimat (TPOXX) Recommendation

Preamble: Tecovirimat (TPOXX) is an antiviral medication that may be used with uncertain benefit in individuals with monkeypox. In Canada, oral tecovirimat (TPOXX) capsules are allocated from the National Emergency Strategic Stockpile. The province of Nova Scotia has one treatment course reserved for those who may benefit. Additional supply may be allocated when this treatment course is used.

Tecovirimat (TPOXX) Recommendation: Consider use on an individual patient basis in those who may benefit including those with, or at risk of, severe laboratory-confirmed monkeypox disease. Infectious diseases consultation is required. Patients should be aware of the limited, case-series level data supporting the recommendation.

Consideration for use on an individual patient basis will be guided by the following clinical situations until further clinical data is available:

Clinical situation 1: Treatment in individuals who have a documented laboratory-confirmed diagnosis with severe monkeypox requiring care in an intensive care setting (for example in those who have monkeypox encephalitis, hypovolemic shock and/or threat to critical organ function)

Clinical situation 2: Treatment in individuals who have a documented laboratory-confirmed diagnosis with progressive infection with severe disease that require hospitalization for monkeypox

Clinical situation 3: Patients who have a documented laboratory confirmed monkeypox diagnosis in the outpatient setting who:

- are pregnant, due to higher risk of adverse pregnancy outcomes
- have progressive infection and are severely immunocompromised
- have keratitis due to the risk of blindness or visual impairment
- have atopic dermatitis with significant skin lesions

Definitions:

- **Severe disease**: Requires hospitalization for supportive care
- **Supportive care**: Examples include, but are not limited to, re-hydration, pain control, and intensive care
- **At risk of severe disease**: Examples include severe immunocompromise, individuals with HIV, pregnant individuals, and individuals with keratitis
- **Severe immunocompromise**: May include but are not limited to post-hematopoietic stem cell transplantation or primary immunodeficiency disorders with B-cell depletion, or anti-B cell therapy (monoclonal antibodies targeting B-cell antigens such as CD19, CD20, CD22, CD30 or BAFF [e.g., ocrelizumab, rituximab, ofatumumab, alemtuzumab, obinutuzumab, blinatumomab, daratumumab, basiliximab, brentuximab, belimumab])

Approved: COVID Network September 20, 2022